Pages that link to "Q42014031"
Jump to navigation
Jump to search
The following pages link to Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients (Q42014031):
Displaying 50 items.
- Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia (Q24200302) (← links)
- Oral deferiprone for iron chelation in people with thalassaemia (Q24200309) (← links)
- Oral deferiprone for iron chelation in people with thalassaemia (Q24244045) (← links)
- Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia (Q24245574) (← links)
- Desferrioxamine mesylate for managing transfusional iron overload in people with thalassaemia (Q24247855) (← links)
- An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major (Q28137956) (← links)
- Ascorbate and deferoxamine administration after chlorine exposure decrease mortality and lung injury in mice (Q28392032) (← links)
- Iron as the malignant spirit in successful ageing (Q30717973) (← links)
- Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial (Q33355411) (← links)
- NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes (Q33393647) (← links)
- Safety and efficacy of deferasirox in multitransfused Indian children withβ‐thalassaemia major (Q33393791) (← links)
- Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia (Q33407282) (← links)
- Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases (Q33736294) (← links)
- Thalassaemia: clinical management (Q33953628) (← links)
- Oral iron chelation therapy for thalassaemia: an uncertain scene (Q34089100) (← links)
- Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). (Q34094838) (← links)
- Advances in iron chelation: an update (Q34174307) (← links)
- Chelation therapy in beta-thalassemia: an optimistic update (Q34404499) (← links)
- Oral iron chelation with deferiprone (Q34418689) (← links)
- Practical management of iron overload. (Q34434629) (← links)
- Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine (Q34534842) (← links)
- Desferrithiocin: a search for clinically effective iron chelators. (Q34631577) (← links)
- The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy (Q35545150) (← links)
- Compliance assessed by the Medication Event Monitoring System (Q35627309) (← links)
- Management of transfusional iron overload - differential properties and efficacy of iron chelating agents (Q35683841) (← links)
- Purging iron from the heart. (Q35775328) (← links)
- The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: an in vivo study. (Q36868160) (← links)
- Management of the thalassemias (Q36870253) (← links)
- Light and shadows in the iron chelation treatment of haematological diseases (Q36894343) (← links)
- Iron overload in myelodysplastic syndromes (Q37093678) (← links)
- Overview of iron chelation therapy with desferrioxamine and deferiprone. (Q37650457) (← links)
- Myelodysplastic syndromes: clinical practice guidelines in oncology (Q37723847) (← links)
- Iron chelation therapy in the management of transfusion-related cardiac iron overload. (Q37992181) (← links)
- Connectivity mapping uncovers small molecules that modulate neurodegeneration in Huntington's disease models (Q38591038) (← links)
- Oral iron-chelating therapy: the L1 experience (Q40607123) (← links)
- Iron overload cardiomyopathies: new insights into an old disease (Q40702958) (← links)
- Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases (Q40791618) (← links)
- Blood transfusion in beta thalassaemia major. (Q40995953) (← links)
- The transport of two iron chelators, desferrioxamine B and L1, across Caco-2 monolayers (Q41478143) (← links)
- A Risk-Benefit Assessment of Iron-Chelation Therapy (Q41682192) (← links)
- Recent advances in β-thalassemias (Q41973193) (← links)
- Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response (Q42183461) (← links)
- Oral iron chelation is here (Q43265591) (← links)
- Enhanced biliary iron excretion with amphiphilic diethylenetriaminepentaacetic acid (Q43820049) (← links)
- Iron complexes of deferiprone and dietary plant catechols as cytoprotective superoxide radical scavengers(1). (Q43832282) (← links)
- A novel V(IV)O-pyrimidinone complex: synthesis, solution speciation and human serum protein binding (Q44206373) (← links)
- Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry (Q44465468) (← links)
- Do we need more iron-chelating drugs? (Q44555183) (← links)
- Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. (Q46922765) (← links)
- Long-term trials of deferiprone in Cooley's anemia. (Q47824588) (← links)